FDA Panel Votes Against AstraZeneca’s Breast Cancer Drug

AstraZeneca Plc failed to persuade a US regulatory review panel about the benefits of its novel breast cancer medicine, creating a hurdle for one of the key drugs in the company’s pipeline.